Tysabri for children with MS

A study of 20 children with MS has found that natalizumab (Tysabri) had a big effect on reducing relapses (from an average of 3.77 a year to 0.4). Half of participants experienced side effects (including weakness and anaemia) and two developed neutralising antibodies that stopped the drug working. MedPage Today Natalizumab (Tysabri) - A to Z of MS
Source: Multiple Sclerosis Trust - Category: Neurology Source Type: news